A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)-Reference-Cited by-同舟云学术

A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)

Published:2013-01-21 Issue:1 Volume:161 Page:68-75
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Mascarenhas John¹,Lu Min¹,Li Timmy¹,Petersen Bruce²,Hochman Tsivia³,Najfeld Vesna,Goldberg Judith D.³,Hoffman Ronald¹

Affiliation:

1. Division of Hematology; Tisch Cancer Institute; Mount Sinai School of Medicine; New York; NY; USA

2. Division of Pathology; Mount Sinai School of Medicine; New York; NY; USA

3. Division of Biostatistics; New York University School of Medicine; New York; NY; USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12220/fullpdf

Reference17 articles.

1. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges;Atadja;Cancer Letters,2009

2. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment;Barosi;Leukemia,2008

3. Improving survival trends in primary myelofibrosis: an international study;Cervantes;Journal of Clinical Oncology,2012

4. A phase II trial of panobinostat, an orally available deacetylase inhibitor (DACi), in patients with primary myelofibrosis (PMF), post essential thrombocythemia (ET), and post polycythemia vera (PV) myelofibrosis;De Angelo;Blood,2010

5. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system;Dupriez;Blood,1996

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer;Pharmacological Reviews;2022-12-08

2. A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis;HemaSphere;2022-08

3. Epigenetic Dysregulation of Myeloproliferative Neoplasms;Hematology/Oncology Clinics of North America;2021-04

4. N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms;Journal of Medicinal Chemistry;2020-11-30

5. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms;Frontiers in Immunology;2020-11-30